beta

ZYME

Zymeworks BC Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.

Market Cap: 856 Million

Primary Exchange: NASDAQ

Website: https://www.zymeworks.com/

Shares Outstanding: 70 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.170940225299762

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 441 trading days

From: 2018-06-01 To: 2019-06-07

Lowest Point:

Zymeworks to Present at Raymond James Life Sciences and MedTech Conference

via: Business Wire at 2019-06-12 13:00:00:000

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Raymond James Life Sciences and MedTech Conference taking place June 18-19, 2019 in New York, NY. The Compa… read more...

Zymeworks to Present at Raymond James Life Sciences and MedTech Conference

via: Business Wire at 2019-06-12 13:00:00:000

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Raymond James Life Sciences and MedTech Conference taking place June 18-19, 2019 in New York, NY. The Compa… read more...

Zymeworks: Leader In Bispecifics Space Makes Substantial Headway

via: SeekingAlpha at 2019-06-11 02:07:59:000

Shares of Zymeworks ( ZYME ) have nearly doubled since I suggested that readers "buy the dip" in February 2018. In that article, I pointed out that a bet on the stock was not merely a wager on prospects for lead program ZW25, but also on its impressive platform technologies with several part… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud